SecBot SecBot
8-K ·Filed May 7, 2026

CPRX

CATALYST PHARMACEUTICALS, INC.
BULLISH
Impact 9/10
Horizonweeks Processed6mo ago SEC0001193125-26-210518
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

Shares will likely trade near the $31.50 offer price with a small spread reflecting regulatory and shareholder approval risk. The stock could trade at a slight discount until the shareholder vote and HSR clearance are obtained. Traders should monitor the proxy filing and regulatory calendar for closing timeline updates.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$31.17
T+0 close · May 7, 2026 · via day close
Latest settled
+0.35%
T+20 · $31.28
Vs SPY
−2.78%
α at T+20
Next horizon
T+60
due 4mo ago
  1. T+0 · May 7 $31.17entry
  2. T+1 · 6mo ago −0.06%α −0.89% · $31.15
  3. T+5 · 6mo ago −0.03%α −1.54% · $31.16
  4. T+20 · 6mo ago +0.35%α −2.78% · $31.28
  5. T+60 · due 4mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Catalyst Pharmaceuticals (CPRX) has entered into a definitive agreement to be acquired by Angelini Pharma for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. The price reflects a 28% premium to the 30-day volume-weighted average price. Separately, Catalyst resolved all remaining FIRDAPSE patent litigation, with Hetero agreeing not to launch a generic version before January 2035, strengthening the IP outlook for the flagship product.

Key Financial Metrics

Deal Value
$4.1B
Premium
28%
Deal Type
merger

Key Facts

  • Acquisition price: $31.50 per share in cash
  • Total equity value: ~$4.1 billion
  • Premium: 28% to unaffected 30-day VWAP as of April 22, 2026
  • Expected closing: Q3 2026
  • Transaction not subject to financing condition
  • Boards of both companies unanimously approved
  • Termination fee payable by Catalyst: $155.5 million
  • Patent settlement with Hetero pushes generic FIRDAPSE entry to at least January 2035
  • All directors and executive officers entered into voting agreements to support the deal

Financial Impact

Stockholders to receive $31.50 per share in cash, totaling approximately $4.1 billion equity value

stock priceenterprise value

Risk Factors

  • Failure to obtain required regulatory approvals (HSR Act)
  • Shareholder vote fails to adopt the merger agreement
  • Superior proposal triggers termination and $155.5M break fee
  • Material adverse effect between signing and closing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-210518
Document: d90722d8k.htm0001193125-26-210518
Document: d90722dex101.htm0001193125-26-210518
Document: d90722dex991.htm0001193125-26-210518
Document: d90722dex992.htm0001193125-26-210518
Document: d90722dex31.htm0001193125-26-210518
Document: 0001193125-26-210518-index-headers.html0001193125-26-210518
Document: 0001193125-26-210518-index.html0001193125-26-210518
Document: 0001193125-26-210518.txt0001193125-26-210518

Track record

16 reports on CPRX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
  2. Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
  3. Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
  4. Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
  5. Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
  6. Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
  7. Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
  8. Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
  9. May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
  10. May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026